CNY 13.73
(-0.94%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 912.84 Million CNY | -3.89% |
2022 | 1.04 Billion CNY | -6.09% |
2021 | 1.17 Billion CNY | -9.62% |
2020 | 1.16 Billion CNY | 14.69% |
2019 | 1.16 Billion CNY | 17.75% |
2018 | 1.01 Billion CNY | 29.65% |
2017 | 769.84 Million CNY | 16.71% |
2016 | 670.86 Million CNY | 28.98% |
2015 | 506.86 Million CNY | 8.93% |
2014 | 463.51 Million CNY | 115.85% |
2013 | 217.97 Million CNY | 104.79% |
2012 | 104.4 Million CNY | 17.19% |
2011 | 92.94 Million CNY | 18.0% |
2010 | 75.65 Million CNY | 17.11% |
2009 | 64.68 Million CNY | 12.03% |
2008 | 60.47 Million CNY | 97.99% |
2007 | 28.42 Million CNY | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 200.6 Million CNY | 22.57% |
2024 Q3 | 88.72 Million CNY | -33.05% |
2024 Q2 | 132.52 Million CNY | -30.78% |
2023 Q3 | 305.02 Million CNY | 25.53% |
2023 Q4 | 156.18 Million CNY | -48.79% |
2023 Q1 | 212.02 Million CNY | 8.16% |
2023 FY | - CNY | -3.89% |
2023 Q2 | 242.98 Million CNY | 14.6% |
2022 FY | - CNY | -6.09% |
2022 Q1 | 221.78 Million CNY | -19.69% |
2022 Q4 | 196.03 Million CNY | -35.09% |
2022 Q3 | 302 Million CNY | 39.13% |
2022 Q2 | 217.06 Million CNY | -2.13% |
2021 Q3 | 257.78 Million CNY | -12.74% |
2021 FY | - CNY | -9.62% |
2021 Q2 | 295.42 Million CNY | 41.61% |
2021 Q1 | 208.61 Million CNY | -46.99% |
2021 Q4 | 276.14 Million CNY | 7.12% |
2020 Q2 | 254.18 Million CNY | 50.9% |
2020 Q4 | 393.5 Million CNY | 8.11% |
2020 FY | - CNY | 14.69% |
2020 Q1 | 168.44 Million CNY | -32.5% |
2020 Q3 | 363.98 Million CNY | 43.19% |
2019 FY | - CNY | 17.75% |
2019 Q3 | 278.82 Million CNY | -7.21% |
2019 Q1 | 277.94 Million CNY | 53.14% |
2019 Q4 | 249.55 Million CNY | -10.5% |
2019 Q2 | 300.48 Million CNY | 8.11% |
2018 FY | - CNY | 29.65% |
2018 Q3 | 271.04 Million CNY | -1.42% |
2018 Q1 | 240.59 Million CNY | 18.54% |
2018 Q2 | 274.94 Million CNY | 14.27% |
2018 Q4 | 181.5 Million CNY | -33.04% |
2017 Q4 | 202.96 Million CNY | 20.36% |
2017 Q2 | 193.45 Million CNY | 3.55% |
2017 FY | - CNY | 16.71% |
2017 Q1 | 186.82 Million CNY | 23.03% |
2017 Q3 | 168.63 Million CNY | -12.83% |
2016 FY | - CNY | 28.98% |
2016 Q4 | 151.85 Million CNY | -9.78% |
2016 Q1 | 155.74 Million CNY | 26.1% |
2016 Q2 | 163.5 Million CNY | 4.99% |
2016 Q3 | 168.31 Million CNY | 2.94% |
2015 Q3 | 120.9 Million CNY | -2.19% |
2015 Q1 | 118.9 Million CNY | -51.63% |
2015 Q2 | 123.61 Million CNY | 3.96% |
2015 FY | - CNY | 8.93% |
2015 Q4 | 123.5 Million CNY | 2.15% |
2014 Q2 | 212.04 Million CNY | 377.86% |
2014 FY | - CNY | 115.85% |
2014 Q4 | 245.8 Million CNY | 169.91% |
2014 Q3 | 91.06 Million CNY | -57.05% |
2014 Q1 | 44.37 Million CNY | -52.94% |
2013 Q2 | 65.18 Million CNY | 171.85% |
2013 Q3 | 37.77 Million CNY | -42.06% |
2013 Q1 | 23.97 Million CNY | 10.18% |
2013 Q4 | 94.29 Million CNY | 149.63% |
2013 FY | - CNY | 104.79% |
2012 Q4 | 21.76 Million CNY | 2.86% |
2012 FY | - CNY | 17.19% |
2012 Q2 | 34.67 Million CNY | 114.63% |
2012 Q3 | 21.15 Million CNY | -38.98% |
2012 Q1 | 16.15 Million CNY | -54.64% |
2011 Q3 | 15.54 Million CNY | -45.95% |
2011 Q1 | 12.19 Million CNY | -49.09% |
2011 Q2 | 28.76 Million CNY | 136.0% |
2011 Q4 | 35.61 Million CNY | 129.07% |
2011 FY | - CNY | 18.0% |
2010 Q2 | 23.07 Million CNY | 171.75% |
2010 Q4 | 23.94 Million CNY | 59.71% |
2010 Q3 | 14.99 Million CNY | -35.03% |
2010 FY | - CNY | 17.11% |
2010 Q1 | 8.49 Million CNY | -48.18% |
2009 Q3 | 18.8 Million CNY | 0.0% |
2009 Q4 | 16.38 Million CNY | -12.84% |
2009 FY | - CNY | 12.03% |
2008 FY | - CNY | 97.99% |
2007 FY | - CNY | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Yixintang Pharmaceutical Group Co., Ltd. | 2.18 Billion CNY | 58.167% |
ZJAMP Group Co., Ltd. | 1.51 Billion CNY | 39.747% |
Luyan Pharma Co.,Ltd. | 819.73 Million CNY | -11.359% |
Ji Yao Holding Group Co., Ltd. | -225.02 Million CNY | 505.663% |